Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

These results tout the potential Eli Lilly's Taltz-Zepbound as the new SoC for PsA patients with comorbid obesity.

UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment of adult patients with moderate to ...

Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?

Evidation, the leader in direct-from-participant real-world data and health research, is announcing the launch of a first-of-its-kind temporal biospecimen collection platform to support multiomics ...